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and synapse damage caused by amyloid-β
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ABSTRACT
Cholesterol is required for the formation and function of some
signalling platforms. In synaptosomes, amyloid-β (Aβ) oligomers,
the causative agent in Alzheimer’s disease, bind to cellular prion
proteins (PrPC) resulting in increased cholesterol concentrations,
translocation of cytoplasmic phospholipase A2 (cPLA2, also known as
PLA2G4A) to lipid rafts, and activation of cPLA2. The formation of Aβ-
PrPC complexes is controlled by the cholesterol ester cycle. In this
study, Aβ activated cholesterol ester hydrolases, which released
cholesterol from stores of cholesterol esters and stabilised Aβ-PrPC
complexes, resulting in activated cPLA2. Conversely, cholesterol
esterification reduced cholesterol concentrations causing the
dispersal of Aβ-PrPC complexes. In cultured neurons, the
cholesterol ester cycle regulated Aβ-induced synapse damage;
cholesterol ester hydrolase inhibitors protected neurons, while
inhibition of cholesterol esterification significantly increased Aβ-
induced synapse damage. An understanding of the molecular
mechanisms involved in the dispersal of signalling complexes is
important as failure to deactivate signalling pathways can lead to
pathology. This study demonstrates that esterification of cholesterol is
a key factor in the dispersal of Aβ-induced signalling platforms
involved in the activation of cPLA2 and synapse degeneration.
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INTRODUCTION
The cellular prion protein (PrPC) gained notoriety for its role in the
transmissible spongiform encephalopathies after undergoing
transformation to the disease-associated isoform (PrPSc). While
the normal role of PrPC remains unclear, reports that PrPC is
concentrated at synapses (Herms et al., 1999), and that transgenic
mice in which the gene for PrP had been knocked-out [Prnp(0/0)]
showed synaptic and memory deficits (Maglio et al., 2006), suggest
that it plays a role in neurotransmission. PrPC is attached to cell
membranes via a glycosylphosphatidylinositol (GPI) anchor (Stahl
et al., 1987), which targets the protein to specific membrane micro-
domains called lipid rafts (Taraboulos et al., 1995). Many lipid rafts
are enriched with signalling molecules and act as platforms in which
GPI anchors interact with signalling proteins (Sharma et al., 2004;
Suzuki et al., 2007). PrPC is associated with numerous cell
signalling pathways, including those of the tyrosine kinase Fyn
(Mouillet-Richard et al., 2000), protein kinase A (Chiarini et al.,
2002) and cytoplasmic phospholipase A2 (cPLA2, also known as
PLA2G4A) (Bate et al., 2010). The formation of signalling
complexes can be triggered by the cross-linkage of lipid raft
components, including the oligomerization of GPI-anchored
proteins (Hammond et al., 2005; Lingwood et al., 2008). PrPC
acts as a scaffold protein that organises signalling complexes
(Linden et al., 2012), and in neurons the clustering of specific GPIs
attached to PrPC caused aberrant cell signalling and synapse
degeneration (Bate and Williams, 2012). Because GPI-anchored
proteins are surrounded by a shell of membrane lipids (Anderson
and Jacobson, 2002), the selective associative properties of
cholesterol, sphingolipids and GPI-anchored proteins are capable
of altering raft composition and function (Lingwood and Simons,
2010). The aggregation of GPIs attached to PrPC is thought to alter
the composition of the underlying cell membrane, leading to cell
activation in a process similar to that reported in T cell signalling
(Chen et al., 2006; Suzuki et al., 2007).
Synaptic abnormalities are caused by aggregated PrPC (Chiesa
et al., 2008) and by cross-linkage of PrPC with monoclonal
antibodies (mAbs) (Solforosi et al., 2004). More recently, PrPC was
identified as a receptor for amyloid-β (Aβ) oligomers (it is
predominantly Aβ42 and Aβ40 peptides that are associated with
disease) (Laurén et al., 2009) that are responsible for the synapse
degeneration and cognitive decline in patients with Alzheimer’s
disease (AD) (Selkoe, 2002; Shankar et al., 2008). Cross-linkage of
PrPC by Aβ oligomers forms a signalling complex containing
activated cPLA2 (Bate and Williams, 2011) and leads to the
production of platelet-activating factor (PAF) and prostaglandins
(PGs). The observations that cPLA2 is highly enriched at synapses
(Moskowitz et al., 1983), and that PAF and PGs affect synaptic
plasticity and memory formation (Chen and Bazan, 2005; Koch
et al., 2010), suggest that controlled activation of this enzyme is a
normal aspect of synapse function. However, aberrant activation of
cPLA2 is associated with synapse degeneration and clinical
symptoms as the concentrations of PGE2 and PAF are increased
in the brains of AD patients when compared with non-demented
controls (Montine et al., 1999; Ryan et al., 2009).
Cholesterol is highly enriched in synaptic membranes and the
fine tuning of cholesterol dynamics is thought to underlie synapse
plasticity and hence memory (Linetti et al., 2010). Given that the
formation and function of lipid rafts depends upon cholesterol
concentrations (Rajendran and Simons, 2005), it follows that
fluctuations in cholesterol concentrations alter the functions of lipid
rafts. The key finding in this study was that the addition of soluble
Aβ oligomers, highly toxic forms of Aβ (Yang et al., 2017),
increased synaptic cholesterol concentrations. Soluble Aβ
oligomers isolated from brain extracts had effects at picomolar
concentrations, concentrations similar to those in cerebrospinal fluid
(Mc Donald et al., 2010; McLean et al., 1999). The increase in
cholesterol was accompanied by a corresponding decrease in
cholesterol esters and was blocked by selective cholesterol esterReceived 25 April 2017; Accepted 26 July 2017
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hydrolase (CEH) inhibitors. Pre-treatment of synaptosomes with
CEH inhibitors also reduced the formation of Aβ-PrPC complexes,
the Aβ-induced translocation cPLA2 to lipid rafts and activation of
cPLA2. In cultured neurons, CEH inhibitors reduced Aβ-induced
synapse degeneration.
The dissociation of signalling platforms is thought to be a
physiological process that limits the intensity of cell signalling.
Consequently, conditions that prevent the dissociation of signalling
platforms may lead to sustained activation, cell disruption and
pathology. This study shows that in synaptosomes, esterification
of cholesterol dispersed Aβ-PrPC complexes and reduced cell
signalling, and in neuronal cultures it reduced Aβ-induced synapse
damage. Our results are consistent with the hypothesis that the
esterification of cholesterol is a key component mediating the
dissociation of Aβ-induced signalling platforms involved in synapse
damage.
RESULTS
SolubleAβ increasescholesterol concentrations in synapses
As soluble Aβ oligomers are too small to be identified via electron
microscopy (Walsh et al., 2002), they were characterised using gel
electrophoresis. Brain extracts contained Aβmonomers, dimers and
trimers that were removed following immunodepletion with mAb
4G8 (reactive with epitopes 17–24 of Aβ) (Fig. 1A). The addition of
brain extracts containing 1 nM Aβ42 significantly increased the
concentrations of cholesterol within synaptosomes (Fig. 1B).
Immunodepletion with mAb 4G8 reduced the concentrations of
Aβ42 (1±0.07 nM compared with 0.03±0.015 nM, n=9, P<0.01)
and Aβ40 (4.36±0.22 nM compared with 0.24±0.07 nM, n=9,
P<0.01) in brain extracts, while immunodepletion with mAb 3F4
(reactive with human prion proteins, mock-depletion) had no
significant effect on either Aβ42 (1±0.07 nM compared with 0.98
±0.08 nM, n=9, P=0.38) or Aβ40 (4.36±0.22 nM compared with
4.15±0.28 nM, n=9, P=0.45). Aβ-depleted brain extracts did not
alter synaptic cholesterol concentrations, indicating that the increase
in cholesterol was triggered by Aβ. The addition of brain extract
containing 1 nM Aβ42 to synaptosomes from neurons derived from
Prnp knockout(0/0) mice did not significantly alter cholesterol
concentrations (0.83±0.07 μM compared with 0.87±0.07 μM,
P=0.23, n=9).
The addition of Aβ oligomers caused a dose-dependent increase
in synaptic cholesterol concentrations, whereas Aβ monomers had
no significant effect (Fig. 1C). Pre-treatment with 1 μM
squalestatin, a squalene synthetase inhibitor (Baxter et al., 1992),
did not significantly alter the Aβ-induced increase in synaptic
cholesterol concentrations (Fig. 1D), indicating that Aβ did
not stimulate cholesterol synthesis. The addition of brain extracts
to synaptosomes reduced the concentrations of cholesterol
esters, and there was a significant inverse correlation between
the concentrations of cholesterol and cholesterol esters in
synaptosomes incubated with brain extract containing 0.125–
1 nM Aβ42 (Fig. 1E). However, the effects of Aβ on synaptic
cholesterol were transient; changes in cholesterol/cholesterol ester
concentrations were seen 1 and 2 h after the addition of 1 nM Aβ42
but had returned to normal after 4 h (Fig. 1F). Collectively, these
findings suggest that the Aβ-induced increase in cholesterol was
provided by the hydrolysis of cholesterol esters (Fig. 1G).
The cholesterol ester cycle controls the Aβ-induced increase
in cholesterol
This hypothesis was tested using the CEH inhibitors
diethylumbelliferyl phosphate (DEUP) (Gocze and Freeman,
Fig. 1. The Aβ-induced increase in cholesterol is mediated by hydrolysis
of cholesterol esters. (A) Immunoblot showing forms of Aβ in brain extract (1)
and in Aβ-depleted brain extract (2). (B) The concentrations of cholesterol in
synaptosomes incubated with control medium, brain extracts, and Aβ-depleted
or mock-depleted brain extracts. Values are mean±s.d. from triplicate
experiments performed three times (n=9). The asterisk indicates cholesterol
concentrations significantly lower than in synaptosomes incubated with brain
extract (t-test, P<0.01). (C) The concentrations of cholesterol in synaptosomes
incubated with oligomer (▪) or monomer (□) preparations containing Aβ42 as
shown. Values are mean±s.d. from triplicate experiments performed three
times (n=9). (D) The concentrations of cholesterol in synaptosomes treated
with control medium or 1 μM squalestatin (SQ) (□) or pre-treated with control
medium or 1 μM SQ and incubated with brain extract containing 1 nM Aβ42 (▪).
Values are mean±s.d. from triplicate experiments performed three times; n=9.
The asterisks indicate concentrations of cholesterol significantly higher than in
control synaptosomes (t-test, P<0.01). (E) There was a significant inverse
correlation between the concentrations of cholesterol and cholesterol esters in
synaptosomes incubated with brain extract containing Aβ42 (0.125–1 nM;
Pearson’s coefficient=−0.93, P<0.01). (F) The concentrations of cholesterol
(●) and cholesterol esters (◊) in synaptosomes incubated with brain extract
containing 1 nMAβ42 for the indicated time periods. Values aremean±s.d. from
triplicate experiments performed three times; n=9. (G) Schematic of the
proposed control of synaptic cholesterol concentrations via Aβ-induced
activation of CEH and ACAT.
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1992) and cholesteryl N-(2-dimethylaminoethyl) carbamate (Hosie
et al., 1987). Pre-treatment of synaptosomes with either 20 µM
DEUP or 5 µM cholesteryl N-(2-dimethylaminoethyl) carbamate
inhibited both the Aβ-induced increase in cholesterol concentrations
(Fig. 2A) and the Aβ-induced reduction in cholesterol esters
(Fig. 2B). These drugs did not affect the concentrations of
cholesterol or cholesterol esters in control synaptosomes.
To determine whether acetyl-coenzyme A acetyltransferases
(ACAT), an enzyme that esterifies cholesterol in cell membranes
(Chang et al., 2006), was involved in regulating Aβ-induced
changes in membrane cholesterol concentrations, neurons were
treated with the ACAT inhibitors (TMP-153) (Sugiyama et al.,
1995) or YIC-C8-434 (Kaneko et al., 2001). First, the efficacy of
ACAT inhibitors was determined by incubating neurons with
squalene. The addition of 5 μM squalene, which was converted to
cholesterol and subsequently esterified by ACAT, resulted in high
concentrations of cholesterol esters in synaptosomes (Fig. 2C). Pre-
treatment of neurons with either TMP-153 or YIC-C8-434 reduced
the squalene-induced increase in cholesterol esters, indicating
inhibition of ACAT (Fig. 2D). At concentrations of 100 nM, both
TMP-153 and YIC-C8-434 fully blocked the squalene-induced
increase in cholesterol ester concentrations. Subsequently, pre-
treatment of synaptosomes with 100 nM TMP-153 or YIC-C8-434
significantly enhanced the Aβ-induced increase in cholesterol
concentrations (Fig. 2E), providing evidence that ACAT reverses the
Aβ-induced increase in cholesterol.
The cholesterol ester cycle controls PrPC-Aβ complexes
Cholesterol, but not cholesterol esters, affects membrane structure
and function. For example, cholesterol concentrations can affect the
expression of PrPC (Gilch et al., 2006), which acts a receptor for
Aβ42 (Laurén et al., 2009). The addition of brain extract to
synaptosomes caused the formation of PrPC-Aβ complexes
(Fig. 3A). There was a significant correlation between the
Fig. 2. CEH inhibitors block the Aβ-induced increase in cholesterol.
(A,B) The concentrations of cholesterol (A) and cholesterol esters (B) in
synaptosomes pre-treated with CEH inhibitors, 20 µM DEUP or 5 µM
cholesteryl N-(2-dimethylaminoethyl) carbamate, and incubated with control
medium (□) or brain extract containing 1 nM Aβ42 (▪). Values are mean±s.d.
from triplicate experiments performed three times; n=9. The asterisks indicate
concentrations of cholesterol/cholesterol esters significantly different to control
synaptosomes incubated with Aβ (t-test, P<0.01). (C) The concentrations of
cholesterol and cholesterol esters in synaptosomes derived from neurons
treated with control medium (□) or 5 µM squalene (▪). Values are mean±s.d.
from triplicate experiments performed three times; n=9. The asterisk indicates
concentrations of cholesterol esters significantly higher than in control
synaptosomes (t-test, P<0.01). (D) The concentrations of cholesterol esters in
synaptosomes from neurons pre-treated with ACAT inhibitors, TMP-153 (▪) or
YIC-C8-434 (□), and incubated with 5 µM squalene. Values are mean±s.d.
from triplicate experiments performed three times; n=9. The asterisks indicate
concentrations of cholesterol esters significantly lower than in control
synaptosomes incubated with squalene (t-test, P<0.01). (E) The
concentrations of cholesterol in synaptosomes pre-treatedwith controlmedium
(●), 100 nM TMP-153 (▪) or 100 nM YIC-C8-434 (□) and incubated with brain
extract containing 1 nM Aβ42 for the indicated time periods. Values are mean
±s.d. from triplicate experiments performed three times; n=9. The asterisks
indicate cholesterol concentrations significantly higher than in control
synaptosomes incubated with Aβ, (t-test, P<0.01).
Fig. 3. The cholesterol ester cycle regulates PrPC-Aβ complexes. (A) The
amounts of PrPC-Aβ complexes in synaptosomes incubated with brain extract
containing Aβ42 as shown. Values are mean±s.d. from triplicate experiments
performed three times; n=9. (B) Therewas a significant correlation between the
amounts of PrPC-Aβ complexes and concentrations of cholesterol following
the addition of brain extract containing Aβ42 (0.06–1 nM, Pearson’s
coefficient=0.85, P<0.01). (C) The amounts of PrPC-Aβ complexes in
synaptosomes pre-treated with control medium (●), 20 μM DEUP (▴) or 5 µM
cholesteryl N-(2-dimethylaminoethyl) carbamate (▵) and incubated with brain
extract containing 1 nM Aβ42 for the indicated time periods. Values are mean
±s.d. from triplicate experiments performed three times; n=9. The asterisks
indicate significantly less PrPC-Aβ complexes than in control synaptosomes
incubated with Aβ (t-test, P<0.01). (D) The amounts of PrPC-Aβ complexes in
synaptosomes pre-treated with control medium (●), 100 nM TMP-153 (▪) or
100 nM YIC-C8-434 (□) and incubated with brain extract containing 1 nM Aβ42
for the indicated time periods. Values are mean±s.d. from triplicate
experiments performed three times; n=9. The asterisks indicate significantly
more PrPC-Aβ complexes than in control synaptosomes incubated with
Aβ (t-test, P<0.01).
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amounts of PrPC-Aβ complexes and cholesterol concentrations in
synaptosomes incubated with brain extracts containing between
0.06 and 1 nM Aβ42 (Pearson’s coefficient= 0.85, P<0.01)
(Fig. 3B). As both PrPC (Naslavsky et al., 1997) and Aβ
(Kawarabayashi et al., 2004; Williamson et al., 2008) are found
within lipid rafts, the formation of which is cholesterol sensitive
(Schroeder et al., 1994), we hypothesized that cross-linkage of PrPC
by Aβ oligomers stimulated the release of cholesterol that stabilised
PrPC-Aβ complexes. A time course study demonstrated that PrPC-
Aβ complexes were transient (Fig. 3C), as was the Aβ-induced
increase in cholesterol (Fig. 1F), suggesting that PrPC-Aβ
complexes and cholesterol concentrations were linked. Pre-
treatment of synaptosomes with CEH inhibitors [20 μM DEUP or
5 µM cholesteryl N-(2-dimethylaminoethyl) carbamate] reduced
the formation of PrPC-Aβ complexes (Fig. 3C). By contrast, pre-
treatment of synaptosomes with ACAT inhibitors (100 nM TMP-
153 or 100 nM YIC-C8-434) increased the amounts of PrPC-Aβ
complexes after 1, 2 and 4 h (Fig. 3D). Collectively, these results
indicate that esterification of cholesterol is a factor in the
dissociation of PrPC-Aβ complexes.
Aβ activates synaptic cPLA2
Synapse damage occurs in response to aberrant activation of cPLA2
(Bate et al., 2010) and the addition of brain extract containing 1 nM
Aβ42, but not Aβ-depleted brain extract, increased the amounts of
activated (phosphorylated) cPLA2 in synaptosomes (Fig. 4A,B). In
synaptosomes incubated with brain extracts containing 0.125–1 nM
Aβ42 there was a significant correlation between the amounts of
PrPC-Aβ complexes and activated cPLA2 (Fig. 4C). The activation
of cPLA2 is the first step in the production of PGs including PGE2, a
bioactive lipid which causes synapse damage in cultured neurons
(Bate et al., 2010). There was a significant correlation between the
amounts of activated cPLA2 and the concentrations of PGE2
released by synaptosomes (Pearson’s coefficient=0.89, P<0.01)
(Fig. 4D). There were also significant correlations between the
concentrations of cholesterol and the amounts of activated cPLA2
(Pearson’s coefficient=0.75, P<0.01) (Fig. 4E), and concentrations
of PGE2 (Pearson’s coefficient=0.67, P<0.01) (Fig. 4F) in these
synaptosomes.
The activation of cPLA2 is associated with its migration
to specific membranes by an N-terminal lipid-binding motif
(Nalefski et al., 1994). Sucrose density gradients showed that in
synaptosomes the addition of Aβ caused the migration of cPLA2 to
low density lipid rafts (Fig. 5A), without affecting the raft
distribution of synaptophysin or ganglioside GM-1 (Fig. 5B). In
synaptosomes, Aβ caused a dose-dependent translocation of cPLA2
to rafts as defined by their resistant to cold triton X-100 (Fig. 5C).
Immunoprecipitation studies showed that Aβ caused cPLA2 to
colocalize in PrPC-containing rafts (Fig. 5D) (Bate and Williams,
2011). Following the addition of Aβ42 (0.125–1 nM), there were
significant correlations between the amounts of cPLA2 in rafts and
the amounts of activated cPLA2 (Pearson’s coefficient=0.92,
P<0.01) (Fig. 5E) and cholesterol concentrations (Pearson’s
coefficient=0.7, P<0.01) (Fig. 5F). These results support the
hypothesis that the Aβ-induced increase in cholesterol stabilises
raft-associated signalling complexes that attract and activate cPLA2.
CEH inhibitors reduce the Aβ-induced activation of cPLA2
The correlations between cholesterol concentrations, raft-associated
and activated cPLA2 suggested a causal relationship. In
synaptosomes, the Aβ-induced increase in activated cPLA2 was
reduced by pre-treatment with CEH inhibitors [20 μM DEUP or
5 µM cholesteryl N-(2-dimethylaminoethyl) carbamate] (Fig. 6A).
By contrast, pre-treatment of synaptosomes with ACAT inhibitors
(100 nM TMP-153 or 100 nM YIC-C8-434) enhanced the Aβ-
induced activation of cPLA2 (Fig. 6B). Similarly, pre-treatment with
CEH inhibitors reduced, while ACAT inhibitors increased, the Aβ-
induced release of PGE2 from synaptosomes (Fig. 6C). Neither
CEH nor ACAT inhibitors affected the activation of cPLA2 by
phospholipase A2-activating peptide (PLAP, also known as PLAA),
indicating they did not have a direct effect on the enzyme (Fig. 6D).
The Aβ-induced translocation of cPLA2 to rafts was transient
(Fig. 6E) and was reduced by pre-treatment with CEH inhibitors. In
synaptosomes pre-treated with ACAT inhibitors (100 nM TMP-153
or 100 nM YIC-C8-434), cPLA2 remained in rafts longer than in
control synaptosomes following the addition of Aβ (Fig. 6F).
Fig. 4. Aβ-activated cPLA2. (A) The amounts of activated cPLA2 in
synaptosomes incubated with control medium, brain extract, Aβ-depleted brain
extract or mock-depleted brain extract. Values are mean±s.d. from triplicate
experiments performed four times; n=12. The asterisk indicates significantly
less activated cPLA2 than in synaptosomes incubated with brain extract (t-test,
P<0.01). (B) The amounts of synaptophysin and activated (phosphorylated)
cPLA2 in synaptosomes incubated with control medium (1) or with brain extract
containing 1 nM Aβ42 (2). In synaptosomes incubated with brain extract
containing Aβ42 (0.125–1 nM), there were significant correlations between the
amounts of activated cPLA2 and PrPC-Aβ complexes (Pearson’s
coefficient=0.95, P<0.01) (C), and between the amounts of activated cPLA2
and concentrations of PGE2 (Pearson’s coefficient=0.89, P<0.01) (D). There
were also significant correlations between the concentrations of cholesterol
and the amounts of activated cPLA2 (Pearson’s coefficient=0.75, P<0.01) (E),
and between concentrations of cholesterol and PGE2 (Pearson’s
coefficient=0.67, P<0.01) (F), in these synaptosomes.
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CEH inhibitors reduce Aβ-induced synapse damage
The effects of the cholesterol ester cycle on Aβ-induced synapse
damage in cultured neurons were studied. Brain extracts caused the
Aβ-dependent loss of synaptic proteins including synapsin-1,
vesicle-associated membrane protein-1, synaptophysin and
cysteine string protein (CSP, also known as DNAJC5) from
cultured neurons in a tissue culture model of synapse
degeneration (Osborne et al., 2016). Here, the addition of brain
extracts reduced the amounts of synaptophysin (Fig. 7A) and CSP
(Fig. 7B) in neurons, indicative of synapse degeneration. Pre-
treatment with CEH inhibitors (20 μM DEUP or 5 µM cholesteryl
N-(2-dimethylaminoethyl) carbamate) protected cultured neurons
against the Aβ-induced loss of synaptophysin and CSP. By contrast,
pre-treatment of neurons with 100 nM TMP-153 or 100 nM YIC-
C8-434 increased the Aβ-induced loss of synaptophysin (Fig. 7C)
and CSP (Fig. 7D). None of the drugs tested affected synapse
damage caused by PLAP; there were no significant differences in
the amounts of synaptophysin in neuronal cultures incubated with
250 nM PLAP after pre-treatment with control medium or 20 μM
Fig. 6. CEH inhibitors reduce the Aβ-induced activation of cPLA2. (A) The
amounts of activated cPLA2 in synaptosomes pre-treated with control medium
(●), or the CEH inhibitors 20 μM DEUP (▵) or 5 μM cholesteryl N-(2-
dimethylaminoethyl) carbamate (▴), and incubated with brain extract containing
Aβ42 as shown. Values are mean±s.d. from triplicate experiments performed
four times; n=12. (B) The amounts of activated cPLA2 in synaptosomes
pre-treated with control medium (●), or the ACAT inhibitors 100 nM TMP-153 (▪)
or 100 nM YIC-C8-434 (□), and incubated with brain extract containing Aβ42 as
shown. Values are mean±s.d. from triplicate experiments performed four times;
n=12. (C) The concentrations of PGE2 in synaptosomes treated with control
medium, 20 μM DEUP, 5 μM cholesteryl N-(2-dimethylaminoethyl) carbamate,
100 nM TMP-153 or 100 nM YIC-C8-434, and incubated with control medium
(□) or brain extract containing 1 nM Aβ42 (▪). Values are mean±s.d. from
triplicate experiments performed three times; n=9. Concentrations of PGE2
significantly less (*) or more (**) than in control synaptosomes incubated with Aβ
(t-test, P<0.01). (D) The amounts of activated cPLA2 in synaptosomes pre-
treated with control medium (●), 20 μM DEUP (▵), 5 μM cholesteryl N-(2-
dimethylaminoethyl) carbamate (▴), 100 nM TMP-153 (▪) or 100 nM YIC-C8-
434 (□), and incubated with PLAP as shown. Values are mean±s.d. from
triplicate experiments performed four times; n=12. (E) The amounts of cPLA2 in
DRMs (rafts) from synaptosomes pre-treated with control medium (●), CEH
inhibitors, 20 μM DEUP (▵) or 5 μM cholesteryl N-(2-dimethylaminoethyl)
carbamate (▴), and incubated brain extract containing 1 nMAβ42 for the indicated
time periods. Values are mean±s.d. from triplicate experiments performed three
times; n=9. The asterisks indicate amounts of raft cPLA2 significantly less than in
control synaptosomes incubated with Aβ42 (t-test, P<0.01). (F) The amounts of
cPLA2 in DRMs (rafts) from synaptosomes pre-treated with control medium (●),
ACAT inhibitors, 100 nMTMP-153 (▪) or 100 nMYIC-C8-434 (□), and incubated
brain extract containing 1 nM Aβ42 for the indicated time periods. Values are
mean±s.d. from triplicate experiments performed three times; n=9. The asterisks
indicate amounts of raft cPLA2 significantly higher than in control synaptosomes
incubated with Aβ42 (t-test, P<0.01).
Fig. 5. Aβ causes the translocation of cPLA2 to rafts. (A) The amounts of
cPLA2 in fractions from a sucrose density gradient derived from control
synaptosomes (○) or from synaptosomes incubated with brain extract
containing 1 nM Aβ42 (●). Values are mean±s.d. from triplicate experiments
performed three times; n=9. (B) Immunoblots showing the amounts of
synaptophysin, cPLA2 and GM-1 in DRMs (rafts) from synaptosomes
incubated with control medium (1) or with brain extract containing 1 nM Aβ42
(2). (C) The amounts of cPLA2 in DRMs (rafts) derived from synaptosomes
incubated with control medium (□) or with brain extract containing Aβ42 as
shown (▪). Values are mean±s.d., from triplicate experiments performed three
times; n=9. (D) Immunoblots showing PrPC and cPLA2 in immunoprecipitates
from synaptosomes incubated with control medium (1) or with brain extract
containing 1 nM Aβ42 (2). There were significant correlations between the
amounts of cPLA2 in rafts and the amounts of activated cPLA2 (Pearson’s
coefficient=0.92, P<0.01) (E) and the concentrations of cholesterol (Pearson’s
coefficient=0.7, P<0.01) (F) in synaptosomes incubated with brain extract
containing Aβ42 (0.125–1 nM).
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DEUP (31±7 units compared with 36±9 units, P=0.13, n=9) or
5 µM cholesteryl N-(2-dimethylaminoethyl) carbamate (31±7 units
compared with 31±8 units, P=0.73, n=9), 100 nM TMP-153 (31±7
units compared with 36±7 units, P=0.16, n=9) or 100 nM YIC-C8-
434 (31±7 units compared with 33±10 units, P=0.71, n=9).
Squalene increases Aβ-induced synapse damage
An altered cholesterol ester cycle, including the accumulation of
cholesterol esters, has been reported in AD patients (Pani et al.,
2009). To mimic this process, cultured neurons were fed squalene
(0.6–5 µM) for 24 h and synaptosomes were isolated. The addition
of 5 µM squalene did not affect concentrations of synaptophysin (98
±6 units compared with 100±5 units, n=6, P=0.25) or CSP (99±4
units compared with 100±4 units, n=6, P=0.61), indicating that
synaptic density was not altered. Squalene treatment increased the
concentrations of cholesterol esters in synaptosomes (Fig. 8A). The
addition of brain extract induced a significantly larger increase in
cholesterol concentrations in synaptosomes from squalene-treated
neurons than in synaptosomes from control neurons (Fig. 8B). There
was a significant correlation between the cholesterol concentrations
and activated cPLA2 in synaptosomes derived from squalene-
treated neurons incubated with brain extract containing 1 nM Aβ42
(Pearson’s coefficient=0.9, P<0.01) (Fig. 8C). Synaptosomes from
neurons treated with squalene produced higher amounts of activated
cPLA2 in response to Aβ than did synaptosomes from control
neurons (Fig. 8D). Finally, pre-treatment of neurons with 5 μM
squalene significantly enhanced the Aβ-induced loss of
synaptophysin (Fig. 8E) and CSP (Fig. 8F).
DISCUSSION
Here, we show a pivotal role for the cholesterol ester cycle in
controlling the formation and dissociation of signalling complexes
formed in synapses in response to Aβ. More specifically, these
studies demonstrate that transient changes in cholesterol
concentrations control the Aβ-induced activation of cPLA2 at
synapses. Thus, inhibition of CEHs reduced the Aβ-induced rise in
cholesterol, reduced the formation of PrPC-Aβ complexes and the
activation of cPLA2 in synapses, and reduced synapse damage in
neuronal cultures. Conversely, inhibiting the esterification of
cholesterol accentuated the Aβ-induced increase in cholesterol,
stabilised PrPC-Aβ complexes, increased activation of cPLA2 and
increased synapse damage.
Fig. 8. Increased synaptic cholesterol esters are associated with
increased Aβ-induced synapse damage. (A) The concentrations of
cholesterol (□) and cholesterol esters (▪) in synaptosomes derived from
neurons treated with squalene. Values are mean±s.d. from triplicate
experiments performed three times; n=9. The asterisks indicate concentrations
of cholesterol esters significantly higher than in control synaptosomes (t-test,
P<0.01). (B) The concentrations of cholesterol in synaptosomes derived from
neurons treated with control medium or 5 µM squalene (□), and in these
synaptosomes incubated with brain extract containing 1 nM Aβ42 (▪). Values
are mean±s.d. from triplicate experiments performed three times n=9. The
asterisk indicates concentrations of cholesterol significantly higher than in
synaptosomes incubated with Aβ42 (t-test, P<0.01). (C) Therewas a significant
correlation between the concentrations of cholesterol and activated cPLA2 in
synaptosomes derived from neurons treated with squalene (0.6 to 5 µM) and
incubated with brain extract containing 1 nM Aβ42 (Pearson’s coefficient=0.9,
P<0.01). (D) The amounts of activated cPLA2 in synaptosomes from neurons
treated with control medium (●) or 5 µM squalene (○) and incubated with brain
extract containing Aβ42 as shown. Values are mean±s.d. from triplicate
experiments performed three times; n=9. The amounts of synaptophysin (E)
and CSP (F) in neurons pre-treated with control medium (●) or 5 µM squalene
(○) and incubated with brain extract containing Aβ42 as shown. Values are
mean±s.d. from triplicate experiments performed three times; n=9.
Fig. 7. CEH inhibitors protect neurons against Aβ-induced synapse
damage. (A,B) The amounts of synaptophysin (A) and CSP (B) in neurons pre-
treated with control medium (●), 20 μM DEUP (▴) or 5 µM cholesteryl N-(2-
dimethylaminoethyl) carbamate (▵), and incubatedwith brain extract containing
Aβ42 as shown. Values are mean±s.d. from triplicate experiments performed
three times; n=9. (C,D,) The amounts of synaptophysin (C) and CSP (D) in
neurons pre-treated with control medium (●), 100 nM TMP-153 (▪) or 100 nM
YIC-C8-434 (□) and incubated with brain extract containing Aβ42 as shown.
Values are mean±s.d. from triplicate experiments performed three times; n=9.
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It is widely believed that the concentration of cholesterol in cell
membranes is a critical factor involved in neurodegeneration
(Maxfield and Tabas, 2005). Here, we show that physiologically
relevant concentrations of natural Aβ increased cholesterol
concentrations within synaptosomes; an observation that is
consistent with reports of increased cholesterol concentrations in
Aβ-positive synapses in the cortex of AD patients (Gylys et al.,
2007). Although the preparations used in these assays are likely to
contain different fragments of the amyloid precursor protein,
responses were similar when preparations were standardized
according to their Aβ42 content. The Aβ-induced increase in
synaptic cholesterol was not caused by cholesterol synthesis; rather
it was controlled by the cholesterol ester cycle; the Aβ-induced
increase in cholesterol was accompanied by a corresponding
reduction in cholesterol esters, indicating the activation of a CEH.
Inhibition of the Aβ-induced increase in synaptic cholesterol by two
selective CEH inhibitors supported this conclusion. Time course
studies demonstrated that the Aβ-induced increase in cholesterol/
reduction in cholesterol esters was transient. These experiments
could not be reliably extended beyond 4 h due to the degradation of
isolated synaptosomes. CEH inhibitors did not affect the
concentrations of cholesterol in the absence of Aβ, indicating that
the cholesterol ester hydrolysis occurs in response to specific
stimuli.
The concentration of cholesterol in the cell membranes is critical
for the formation of lipid raft membrane platforms that concentrate
molecules involved in cell signalling (Simons and Toomre, 2000).
Specific stimuli cause individual rafts to coalesce to form a larger
platform capable of cell activation (Lingwood et al., 2008;
Lingwood and Simons, 2010). Raft formation is associated with
the oligomerization of proteins (Hammond et al., 2005), including
the aggregation of PrPC by Aβ oligomers (Bate and Williams,
2011). Notably, the increase in synaptic cholesterol concentrations
was associated with the toxic Aβ oligomers (Mc Donald et al., 2010;
McLean et al., 1999) rather than nontoxic Aβ monomers (Giuffrida
et al., 2009). The formation of PrPC-Aβ complexes was also
transient and mirrored the Aβ-induced changes in cholesterol; there
was a close temporal association between concentrations of
cholesterol and PrPC-Aβ complexes. We hypothesise that Aβ
stimulates the hydrolysis of cholesterol esters resulting in the release
of cholesterol that stabilises PrPC-Aβ complexes. Thus, the
inhibition of CEHs reduced the Aβ-induced rise in cholesterol and
consequently the formation of PrPC-Aβ complexes.
The activation of cPLA2 is the first step in the production of
PGE2. Since the concentrations of PGE2 are raised in the
cerebrospinal fluid of patients with AD (Montine et al., 1999) and
PGE2 caused synapse damage in vitro (Bate et al., 2010), we
propose that concentrations of Aβ >1 nM cause aberrant activation
of cPLA2, leading to excess PGE2 production and synapse
degeneration. This hypothesis is supported by the demonstration
of significant correlations between Aβ-induced increases in
cholesterol concentrations, activated cPLA2 and PGE2 in
synapses. Inhibition of CEHs reduced the Aβ-induced activation
of cPLA2 and PGE2 production. As neither CEH nor ACAT
inhibitors affected activation of cPLA2 by PLAP, we concluded that
these drugs did not have a direct effect upon the enzyme. The
activation of cPLA2 involves its translocation to lipid rafts
(Gaudreault et al., 2004), specifically rafts containing PrPC-Aβ
complexes (Bate and Williams, 2011). There were significant
correlations between concentrations of cholesterol, the amounts
of cPLA2 in lipid rafts, the amounts of activated cPLA2 and
concentrations of PGE2 following the addition of Aβ. Furthermore,
time course studies demonstrated that the Aβ-induced rise in
cholesterol, Aβ-PrPC complexes and the translocation of cPLA2
into rafts in synapses were transient and demonstrated a close
temporal correlation. The inhibition of CEH in synaptosomes
reduced both the amounts of cPLA2 and the duration that cPLA2
spent within rafts.
The dissociation of lipid raft platforms is a mechanism that limits
cell signalling. Notably, the return of cholesterol/cholesterol ester
concentrations to basal levels (indicating that cholesterol was being
esterified) was closely associated with the dissociation of Aβ-PrPC
complexes and the return of cPLA2 to the cytoplasm. Thus, the
esterification of cholesterol limited the Aβ-induced increase of
cholesterol in synapses as pharmacological inhibition of ACAT
resulted in high cholesterol concentrations being maintained,
increased Aβ-PrPC complexes, increased time that cPLA2 spent
within rafts, increased activation of cPLA2 and increased PGE2
concentrations. Collectively, these results support the hypothesis
that localised ACAT reduced synaptic cholesterol concentrations
leading to the dissociation of PrPC-Aβ complexes and hence the
cessation of cell signalling. Conditions in which signalling
platforms fail to dissociate may lead to sustained activation of
signalling pathways, leading to cell disruption and disease. Here, we
demonstrate that inhibition of ACAT increased Aβ-induced synapse
damage. It is noteworthy that although this study focused upon
cholesterol and cPLA2, many other aspects of synaptic function are
cholesterol-sensitive and may be influenced by the Aβ-induced
increased cholesterol concentrations.
An altered cholesterol ester cycle in AD patients resulting in
accumulation of cholesterol esters has been reported (Chan et al.,
2012; Pani et al., 2009). The concentrations of cholesterol esters in
synapses were increased by loading neurons with squalene.
Synaptosomes from these neurons showed heightened responses
to Aβ, increased concentrations of cholesterol and greater activation
of cPLA2. Of greater importancewas the observation that Aβ caused
greater synapse damage, as measured by the loss of synaptophysin
and CSP, in squalene-loaded neurons when compared with control
neurons. The role of ACAT in neurodegenerative diseases is
complicated as it may affect different aspects of AD pathogenesis.
ACAT inhibitors have been proposed as treatments for AD because
they reduced the production of Aβ (Bryleva et al., 2010; Puglielli
et al., 2001). However, in those studies ACAT inhibitors were used
throughout the course of the experimental disease. The results
presented here suggest that ACAT inhibitors might accelerate
synapse damage in the presence of Aβ. Consequently, ACAT
inhibitors might be able to prevent the development of AD but
maybe contraindicated in the latter stages of AD, when
concentrations of Aβ are already raised.
In summary, these results demonstrate the role of the cholesterol
ester cycle in Aβ-induced cell signalling at synapses. The release of
cholesterol from stores of cholesterol esters stabilises the complexes
formed between PrPC and Aβ that activate cPLA2. Conversely, the
esterification of cholesterol facilitates the dissociation of PrPC-Aβ
complexes and deactivation of cPLA2.
MATERIALS AND METHODS
Primary neuronal cultures
Primary cortical neurons were prepared from the brains of mouse embryos
(day 15.5) from Prnp wild-type(+/+) and Prnp knockout(0/0) mice after
mechanical dissociation. Neuronal precursors were plated at 5×105 cells/well
in 48-well plates in Hams F12 containing 5% foetal calf serum for 2 h.
Cultures were shaken (600 rpm for 5 min) and non-adherent cells removed
by two washes in PBS. Neurons were subsequently grown in neurobasal
medium containing B27 components (Invitrogen) and nerve growth factor
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(5 ng/ml) (Sigma-Aldrich) for 10 days. Immunohistochemistry revealed
that ∼95% of cells were neurofilament positive. Neurons were
subsequently pre-treated with test compounds for either 24 h (squalene)
or 1 h (CEH or ACAT inhibitors) before the addition of Aβ preparations
or PLAP (Bachem). All experiments were performed in accordance
with European regulations (European Community Council Directive,
1986, 56/609/EEC) and approved by the local authority veterinary
service/ethical committee.
Cell extracts
Treated cells were washed twice in PBS and homogenised in an extraction
buffer containing 10 mM Tris-HCl, 100 mM NaCl, 10 mM EDTA, 0.5%
Nonidet P-40, 0.5% sodium deoxycholate and 0.2% SDS at 106 cells/ml.
Mixed protease inhibitors [4-(2-Aminoethyl) benzenesulfonyl fluoride
hydrochloride, Aprotinin, Leupeptin, Bestatin, Pepstatin A and E-46]
(Sigma-Aldrich) and a phosphatase inhibitor cocktail including PP1, PP2A,
microcystin LR, cantharidin and p-bromotetramisole (Sigma-Aldrich) were
added, and nuclei and large fragments were removed by centrifugation
(1000 g for 5 min).
Western blotting
Samples were mixed with Laemmli buffer containing β-mercaptoethanol,
heated to 95°C for 5 min and proteins were separated by electrophoresis on
15% polyacrylamide gels (PAGE). Proteins were transferred onto a
Hybond-P PVDF membrane by semi-dry blotting. Membranes were
blocked using 10% milk powder; synaptophysin was detected with
MAB368 (Millipore), PrPC with mAb 4F2 (a gift from Professor Jaques
Grassi, CEA, Saclay, France), cPLA2 with goat polyclonal anti-cPLA2
(Santa Cruz Biotechnology, sc-4049), phosphorylated-cPLA2 with rabbit
polyclonal anti-phospho-cPLA2 (Cell Signaling Technology, 2831S) and
GM-1 with biotinylated cholera toxin subunit B (Sigma-Aldrich, C9972)
(all at 1 µg/ml). These were visualised using a 1:1000 dilution of
biotinylated anti-mouse/goat/rat/rabbit IgG (Sigma-Aldrich) followed by
extravidin-peroxidase and enhanced chemiluminescence.
Synaptophysin ELISA
Maxisorb immunoplates (Nunc) were coated with an anti-synaptophysin
mAb (MAB368, Millipore, 1 µg/ml) and blocked with 5% milk powder.
Samples were added for 1 h and bound synaptophysin was detected using
rabbit polyclonal anti-synaptophysin (Abcam, ab53166, 1 µg/ml) followed
by a biotinylated anti-rabbit IgG (Sigma-Aldrich), extravidin-alkaline
phosphatase and 1 mg/ml 4-nitrophenol phosphate solution (Sigma-
Aldrich). Absorbance was measured at 405 nm. Samples were expressed
as ‘units synaptophysin’, where 100 units was the amount of synaptophysin
in 106 untreated cells.
CSP ELISA
Maxisorb immunoplates were coated with 1 µg/ml of a mouse mAb to CSP
(sc-136468, Santa Cruz Biotechnology) and blocked with 5% milk powder.
Samples were added for 1 h and bound CSP was detected using 1 µg/ml
rabbit polyclonal anti-CSP (sc-33154, Santa Cruz Biotechnology) followed
by a biotinylated anti-rabbit IgG, extravidin-alkaline phosphatase and 1 mg/ml
4-nitrophenol phosphate solution. Absorbance was measured at 405 nm.
Samples were expressed as ‘units CSP’, where 100 units was the amount of
CSP in 106 untreated cells.
Isolation of synaptosomes
Synaptosomes were prepared on a discontinuous Percoll gradient as
described (Dunkley et al., 2008). Neurons were homogenised at 4°C in SED
solution (0.32 M sucrose, 50 mM Tris-HCl pH 7.2, 1 mM EDTA, and
1 mM dithiothreitol) and centrifuged at 1000 g at 4°C for 10 min. The
supernatant was transferred to a gradient of 3, 7, 15 and 23% filtered Percoll
prepared in SED solution and centrifuged at 16,000 g for 30 min at 4°C.
Synaptosomes were collected from the interface of the 15% and 23% Percoll
steps, and washed (16,000 g for 5 min at 4°C) and suspended in neurobasal
medium containing B27 components at a concentration equivalent to 5×106
neurons per ml. All synaptosomes were used on the same day of preparation.
After the test period, synaptosomes were homogenised in either extraction
buffer (as above) or in the DRM extraction buffer (below). All
synaptosomes preparations contained equal amounts of synaptophysin.
Isolation of DRMs
Detergent-resistant membranes (DRMs) were isolated by their insolubility
in nonionic detergents as described (London and Brown, 2000). Briefly,
synaptosomes were homogenised in an ice-cold buffer containing 1%Triton
X-100, 10 mM Tris-HCl pH 7.2, 150 mM NaCl, 10 mM EDTA and mixed
protease inhibitors, and nuclei and large fragments were removed by
centrifugation (300 g for 5 min at 4°C). The post-nuclear supernatant was
incubated on ice (4°C) for 1 h and centrifuged (16,000 g for 30 min at 4°C).
The supernatant was reserved as the detergent-soluble membrane (DSM),
while the insoluble pellet was homogenised in an extraction buffer
containing 10 mM Tris-HCl pH 7.4, 150 mM NaCl, 10 mM EDTA, 0.5%
Nonidet P-40, 0.5% sodium deoxycholate, 0.2% SDS and mixed protease
inhibitors at 106 cells/ml and centrifuged (10 min at 16,000 g), and the
soluble material was reserved as the DRM fraction.
Sucrose density gradients
Synaptosomes were homogenised in a buffer containing 250 mM sucrose,
10 mMTris-HCl pH 7.4, 1 mMEGTA, mixed protease inhibitors and 1 mM
dithiothreitol. Particulate membrane fragments and nuclei were removed by
centrifugation (1000 g for 5 min). Membranes were washed by
centrifugation at 16,000 g for 10 min at 4°C and suspended in an ice-cold
buffer containing 1% Triton X-100, 10 mM Tris-HCl pH 7.2, 150 mM
NaCl, 10 mMEDTA. 5–40% sucrose solutions were prepared and layered to
produce a gradient. Solubilised membranes were layered on top and
centrifuged at 50,000 g for 18 h at 4°C. Serial 1 ml aliquots were collected
from the bottom of gradients.
Cholesterol measurement
The concentrations of cholesterol in samples were measured using the
Amplex Red cholesterol assay kit (Life Technologies) based upon Robinet
et al. (2010). Briefly, control and treated synaptosomes were washed (400 g,
10 min) and lipids extracted by suspension in hexane:isopropanol (3:2, v/v)
and disruption for 10 min in a cell disruptor (Disruptor Genie, Scientific
Instruments). Samples were centrifuged (10,000 g, 1 min), and the
supernatants collected and dried under liquid nitrogen. Lipids were
dissolved in 500 μl isopropanol:NP40 (9:1, v/v) and sonicated in a water
bath (30 min). Samples were pre-treated with catalase before the enzyme
cocktail of the Amplex Red kit [0.1 M potassium phosphate buffer pH 7.4,
0.25 M NaCl, 5 mM cholic acid, 0.1% Triton X-100, cholesterol oxidase
(±cholesterol esterase), horse radish peroxidase and 0.4 mM 10-acetyl-3,7-
dihydroxyphenoxazine] was added and incubated at 37°C for 30 min.
Cholesterol is oxidised by cholesterol oxidase to yield hydrogen peroxide
and ketones. The hydrogen peroxide reacts with 10-acetyl-3, 7-
dihydroxyphenoxazine (Amplex Red reagent) to produce highly
fluorescent resorufin, which is measured by excitation at 530 nm and
emission detection at 590 nm. Each experiment contained cholesterol
standards and solvent only controls. Cholesterol concentrations of samples
were calculated by reference to the cholesterol standards.
cPLA2 ELISA/activated cPLA2/PGE2 ELISA
The amounts of cPLA2 in extracts was measured by ELISA as described
(Bate and Williams, 2011). Maxisorb immunoplates were coated with
0.5 µg/ml mouse mAb anti-cPLA2 (clone CH-7, Upstate, 05-568) and
blocked with 5% milk powder in PBS+0.1% Tween 20. Samples were
incubated for 1 h and the amount of bound cPLA2 was detected using
1 µg/ml goat polyclonal anti-cPLA2 (Santa Cruz Biotechnology, sc-4049)
followed by biotinylated anti-goat IgG, extravidin-alkaline phosphatase and
1 mg/ml 4-nitrophenol phosphate solution. Absorbance was measured at
405 nm. The activation of cPLA2 is accompanied by phosphorylation of the
505 serine residue, which creates a unique epitope and can be measured by
ELISA (Bate et al., 2010). To measure the amount of activated cPLA2, an
ELISA using anti-cPLA2 mAb (clone CH-7, Upstate, 05-568) combined
with 1 µg/ml rabbit polyclonal anti-phospho-cPLA2 (Cell Signaling
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Technology, 2831S), followed by biotinylated anti-rabbit IgG (Sigma-
Aldrich), extravidin-alkaline phosphatase and 1 mg/ml 4-nitrophenol
phosphate solution. Absorbance was measured on a microplate reader at
405 nm. Results were expressed as ‘units activated cPLA2’ (1 unit=amount
of activated cPLA2 in control preparations). The amounts of PGE2 in
synaptosomes were determined using a competitive enzyme immunoassay
kit (R&D Systems) according to the manufacturer’s instructions.
Brain extracts
Samples of temporal lobes from three patients with a clinical and
pathologically confirmed diagnosis of AD were supplied by Asterand, an
international supplier of human tissue (informed consent was given to
Asterand, and samples were collected according to the Declaration of
Helsinki, 2000). Soluble extracts were prepared using methodology as
previously described (Shankar et al., 2008). Briefly, brain tissue was cut into
pieces of ∼100 mg and added to 2 ml tubes containing lysing matrix D
beads (Q-Bio). Ice-cold 20 mM Tris HCl pH 7.4 containing 150 mM NaCl
was added to an equivalent of 100 mg brain tissue/ml and tubes were shaken
for 10 min. This process was performed three times before tubes were
centrifuged at 16,000 g for 10 min to remove particulate matter. Soluble
material was prepared by passage through a 50 kDa filter (Sartorius) (16,000
g for 30 min to remove proteolytic enzymes, membrane-bound and plaque
Aβ). The remaining material was then desalted (3 kDa filter, Sartorius) to
eliminate bioactive small molecules and drugs, and the retained material
collected (preparation contains molecules with molecular weights between
3 and 50 kDa). Monomers were prepared by passage through a 10 kDa filter
(Sartorius) and oligomers were collected from the material that was retained
(10–50 kDa). The concentrations of Aβ in each preparation were measured
by ELISA (see below). Preparations were stored at −80°C. For cell
experiments, preparations were diluted in neurobasal medium containing
B27 components. For immunoblots, preparations were mixed with an equal
volume of 0.5% NP-40, 5 mM CHAPS, 50 mM Tris pH 7.4, and separated
by PAGE. Proteins were transferred onto a Hybond-P PVDF membrane by
semi-dry blotting and blocked using 10% milk powder. Aβ was detected by
incubation with 1 µg/ml mAb 6E10, reactive with amino acids 1-16 of Aβ
(Covance, SIG-39340), biotinylated anti-mouse IgG, extravidin-peroxidase
and enhanced chemiluminescence.
Immunodepletions
Brain extracts were incubated with 1 μg/ml mAb 4G8 (reactive with amino
acids 17–24 of Aβ, Covance, SIG-39220) or 1 µg/ml mAb 3F4 (reactive
with human prion proteins, Millipore, MAB1562; mock-depletion) and
incubated at 4°C on rollers for 24 h. Protein G microbeads were added
(10 µl/ml) (Sigma-Aldrich) for 2 h, protein G bound-antibody complexes
removed by centrifugation and the depleted media filtered before use.
Sample preparation for end-specific ELISAs
To detach Aβ from cellular components that occlude specific epitopes,
samples (50 µl) were mixed with 250 µl 70% formic acid and sonicated. A
50 µl aliquot was added to 50 µl 10 M Tris-HCl with protease inhibitors (as
above) and sonicated before addition to ELISA.
Aβ40/Aβ42 ELISA
Nunc Maxisorb immunoplates were coated with 1 µg/ml mAb 4G8 and
blocked with 5% milk powder. Samples were added for 1 h. In separate
plates, Aβ40 was detected with 2 µg/ml rabbit polyclonal PC-149 (Merck)
and Aβ42 with a 1 µg/ml rabbit mAb BA3-9 (Covance, SIG-39168),
followed by biotinylated anti-rabbit IgG, extravidin alkaline phosphatase
(Sigma-Aldrich) and 1 mg/ml 4-nitrophenol phosphate solution.
Absorbance was measured at 405 nm and compared to a dose response of
synthetic Aβ40/Aβ42 (Bachem).
PrPC:Aβ complex ELISA
Maxisorb immunoplates were coated with 1 µg/ml mAb 4F2 reactive with
PrPC (a gift from Professor Jaques Grassi). Plates were blocked with 5%milk
powder and samples were added for 1 h. Aβ bound to PrPC was detected by
1 µg/ml biotinylated mAb 6E10 (reactive with epitopes 1–16 of Aβ,
Covance), followed by extravidin-alkaline phosphatase and 1 mg/ml
4-nitrophenol phosphate solution. Absorbance was measured at 405 nm.
Samples were expressed as a% of themaximumOD in control synaptosomes.
Drugs
Stock solutions were dissolved in ethanol or DMSO, and diluted in culture
medium to obtain final working concentrations. Vehicle controls consisted
of equivalent dilutions of ethanol or DMSO.
Statistical analysis
Comparison of treatment effects was carried out using Student’s paired
t-tests, and one-way and two-way ANOVAwith Bonferroni’s post hoc tests
(IBM SPSS Statistics 20). Data are presented as mean±s.d. and P<0.01 was
considered significant. Correlations between data sets were analysed using
Pearson’s bivariate coefficient (IBM SPSS Statistics 20).
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